MNG607
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.384
- PEROXISOME+0.325
- UV_RESPONSE_DN+0.276
- HEME_METABOLISM+0.237
- MYC_TARGETS_V1+0.210
- BILE_ACID_METABOLISM+0.166
- INTERFERON_ALPHA_RESPONSE+0.158
- NOTCH_SIGNALING+0.143
- MITOTIC_SPINDLE+0.116
- FATTY_ACID_METABOLISM+0.095
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.512
- ANGIOGENESIS-0.408
- ALLOGRAFT_REJECTION-0.392
- HYPOXIA-0.366
- INFLAMMATORY_RESPONSE-0.363
- IL6_JAK_STAT3_SIGNALING-0.357
- APICAL_SURFACE-0.347
- OXIDATIVE_PHOSPHORYLATION-0.307
- P53_PATHWAY-0.304
- PANCREAS_BETA_CELLS-0.304
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03073 | — | cohortA1 | 0.829 |
| 2 | MNG452 | — | — | 0.782 |
| 3 | TCGA-E2-A15P-01A-11R-A115-07 | — | B | 0.770 |
| 4 | MNG37 | — | — | 0.765 |
| 5 | MNG679 | — | — | 0.760 |
| 6 | SJEPD031319_D1.RNA-Seq | EPN | EPN Tumor | 0.753 |
| 7 | BS_3F4FQJMR | Supratentorial Ependymoma | — | 0.750 |
| 8 | BS_3F4FQJMR | EPN | Supratentorial EPN | 0.743 |
| 9 | SRR661290 | GTEX | — | 0.743 |
| 10 | EPT0519 | EPN | Posterior Fossa EPN | 0.742 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.384 | Remibrutinib | — uncovered |
| PEROXISOME | 0.325 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.276 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.237 | Temsirolimus | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.166 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.158 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.143 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.116 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.095 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.087 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.049 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.031 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.017 | Inavolisib | — uncovered |